127 related articles for article (PubMed ID: 37702380)
1. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients.
Yang Y; Huang X; Shi Y; Yang R; Shi H; Yang X; Hao G; Zheng Y; Wang J; Su L; Li Y; Zhao W
Front Pharmacol; 2021; 12():692922. PubMed ID: 34290611
[No Abstract] [Full Text] [Related]
3. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
Khan AR; Raza A; Firasat S; Abid A
Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
[TBL] [Abstract][Full Text] [Related]
5. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
[TBL] [Abstract][Full Text] [Related]
6. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
[TBL] [Abstract][Full Text] [Related]
7. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
Yildirim E; Şahin G; Kaltuş Z; Çolak E
Clin Lab; 2019 Nov; 65(11):. PubMed ID: 31710427
[TBL] [Abstract][Full Text] [Related]
8. The impact of IL-10 and CYP3A5 gene polymorphisms on dose-adjusted trough blood tacrolimus concentrations in early post-renal transplant recipients.
Chen Z; Cheng X; Zhang L; Tang L; Fang Y; Chen H; Zhang L; Shen A
Pharmacol Rep; 2021 Oct; 73(5):1418-1426. PubMed ID: 34089513
[TBL] [Abstract][Full Text] [Related]
9. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
10. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
11. Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.
Uno T; Wada K; Matsuda S; Terada Y; Oita A; Kawase A; Takada M
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):665-673. PubMed ID: 29691732
[TBL] [Abstract][Full Text] [Related]
12. Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes.
Uno T; Wada K; Matsuda S; Terada Y; Terakawa N; Oita A; Yokoyama S; Kawase A; Hosomi K; Takada M
Eur J Clin Pharmacol; 2019 Jan; 75(1):67-75. PubMed ID: 30251062
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
[TBL] [Abstract][Full Text] [Related]
14. Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.
Phupradit A; Vadcharavivad S; Ingsathit A; Kantachuvesiri S; Areepium N; Sra-Ium S; Auamnoy T; Sukasem C; Sumethkul V; Kitiyakara C
Ther Drug Monit; 2018 Oct; 40(5):549-557. PubMed ID: 29878980
[TBL] [Abstract][Full Text] [Related]
15. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.
Ebid AIM; Ismail DA; Lotfy NM; Mahmoud MA; ELSharkawy M
J Clin Pharm Ther; 2022 Dec; 47(12):2255-2263. PubMed ID: 36379901
[TBL] [Abstract][Full Text] [Related]
17. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 Polymorphism in Renal Transplantation: A Key to Personalized Immunosuppression.
Pasari AS; Balwani MR; Gurjar P; Bawankule C; Bhawane A; Tolani P; Kashiv P; Dubey S; Katekhaye VM
Transplant Proc; 2023 Jun; 55(5):1305-1309. PubMed ID: 36973144
[TBL] [Abstract][Full Text] [Related]
19. The Clinical Impact of the C
van Gelder T; Meziyerh S; Swen JJ; de Vries APJ; Moes DJAR
Front Pharmacol; 2020; 11():1142. PubMed ID: 32848756
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients.
Fernando ME; Sellappan M; Srinivasa Prasad ND; Suren S; Thirumalvalavan K
Indian J Nephrol; 2019; 29(4):261-266. PubMed ID: 31423060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]